Afterwards, with the emergence of novel anti-HER2 antibodies, antibody drug conjugates and tyrosine kinase inhibitors (TKIs), dual HER2-targeted therapy became the mainstay for high-risk HER2 + breast cancer (e.g. APHINITY and ExteNET trials) [3, 4]. The gene discussed is ERBB2; the disease is breast carcinoma.